Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Y. A. Vasyuk"'
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 2, Iss 2, Pp 61-66 (2016)
Data about heart rate variability analysis in healthy people and patients with chronic heart failure are reviewed. Prognostic value of time-domain and spectral measures is mentioned. Influence of standard therapy on heart rate variability is describe
Externí odkaz:
https://doaj.org/article/3b2217a3ea604130a916ba1042a54e83
TISSUE DOPPLEROGRAPHY IN EARLY DIAGNOSIS OF FUNCTIONAL MYOCARDIAL DISORDERS IN ARTERIAL HYPERTENSION
Autor:
Y. A. Vasyuk, A. B. Hadzegova, S. V. Ivanova, E. N. Yuschuk, I. M. Amirbegishvili, N. I. Gerasimova
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 4, Iss 1, Pp 39-43 (2016)
Aim. To determine the potential of tissue Dopplerography (TDG) for early diagnosis of functional myocardial disorders in patients with arterial hypertension (HT).Material and methods. 66 patients with HT were examined. Clinical examination, 24-hour a
Externí odkaz:
https://doaj.org/article/faef4d3e57b241ed8c240a3d2fb7aaa5
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 4, Iss 3, Pp 76-82 (2016)
Aim. To assess influence of combined antihypertensive (captopril or metoprolol) and antidepressant (thianeptin or sertralin) therapy on clinical status, blood pressure (BP) and myocardial function in patients with arterial hypertension (HT) and affec
Externí odkaz:
https://doaj.org/article/1c120837c6524204b82ba05ad53b8f30
Autor:
Y. A. Vasyuk, A. V. Lebedev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 3, Iss 4, Pp 39-45 (2015)
A review is devoted to a comorbidity of myocardial infarction and anxious and depressive disorders. In the first part (Rational Pharmacother. Cardiol. 2007;3:41-51) data concerning prevalence of depression in myocardial infarction, pathophysiological
Externí odkaz:
https://doaj.org/article/715c9f372082405996ac5b83c6721ce1
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 3, Iss 1, Pp 41-47 (2015)
So-called “metabolic” direction has been developing intensively during last decades. Its aim is the theoretical and practical analysis of the role of metabolic disorders in initiation and progression of many diseases. The pathogenic peculiarities
Externí odkaz:
https://doaj.org/article/17c966f960154848b5e19352066b90fe
Autor:
L. M. Makarov, V. N. Komolyatova, O. A. Kupriyanova, E. V. Pervova, G. V. Ryabykina, A. V. Sobolev, V. M. Tikhonenko, A. N. Turov, Y. V. Shubik, A. V. Ardashev, R. M. Baevsky, L. A. Balykova, N. A. Beresten, Y. A. Vasyuk, I. A. Gorbunov, V. V. Dolgikh, D. V. Drozdov, D. V. Duplyakov, G. G. Ivanov, I. Kiseleva, E. V. Kovbasova, I. N. Limacina, V. Yu. Mareev, T. V. Tresser, T. V. Tyurina, M. V. Yakovleva, A. V. Pevzner, Yu. M. Pozdnyakov, A. Sh. Revishvili, A. N. Rogoza, P. V. Struchkov, N. N. Fedina, S. I. Fedorova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 2, Pp 6-71 (2014)
Externí odkaz:
https://doaj.org/article/a860e5db597c4db49b5b1c8ddd6a7516
Publikováno v:
Advances in Therapy
Introduction Heart rate (HR) reduction is an integral part of antianginal therapy, but many patients do not reach the guideline-recommended target of less than 60 bpm despite high use of beta-blockers (BB). Failure to uptitrate BB doses may be partly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103b5b3e177e0b55a21e67c6c56dc9c9
https://doi.org/10.1007/s12325-018-0681-5
https://doi.org/10.1007/s12325-018-0681-5
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 3, Iss 1, Pp 41-47 (2015)
So-called “metabolic” direction has been developing intensively during last decades. Its aim is the theoretical and practical analysis of the role of metabolic disorders in initiation and progression of many diseases. The pathogenic peculiarities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19160133d27e3ea9717ef328570a6a88
http://www.rpcardio.ru/jour/article/view/384
http://www.rpcardio.ru/jour/article/view/384
Autor:
E I Tarlovskaya, Yu L Begrambekova, I. V. Fomin, G. E. Gendlin, A. A. Garganeeva, A G Ovchinnikov, S. R. Gilyarevskiy, Dmitry V. Duplyakov, S V Gote, M. Y. Sitnikova, Y N Belenkov, V V Skibitskiy, Yu V Mareev, Evgeny Shlyakhto, T V Dovzhenko, G P Arutyunov, M G Glezer, A. S. Galyavich, N. A. Koziolova, A O Shevchenko, A I Chesnikova, Viacheslav Mareev, N. B. Perepech, Zhanna Kobalava, A V Koroteev, F. T. Ageev, Y M Lopatin, Y A Vasyuk, O. M. Drapkina
Publikováno v:
Kardiologiia. 58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8669bdf5b9ebedcd64fa642088f4f5
https://pubmed.ncbi.nlm.nih.gov/30081796
https://pubmed.ncbi.nlm.nih.gov/30081796
Publikováno v:
Kardiologiia. 56(12)
Anthracyclines including doxorubicin, epirubicin, daunorubicin, aclarubicin are extensively used as chemotherapeutic agents for treatment of hematological and other malignancies. In cancer therapy anthracyclines are often used in combinations with ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b951dec37fc7cf42760929b88e744a6c
https://pubmed.ncbi.nlm.nih.gov/28290807
https://pubmed.ncbi.nlm.nih.gov/28290807